Real-time Estimate
Cboe BZX
11:47:43 2024-05-16 am EDT
|
5-day change
|
1st Jan Change
|
1.295
USD
|
+9.28%
|
|
+0.39%
|
-52.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,641
|
7,350
|
531.7
|
717.4
|
238.8
|
104.9
|
-
|
-
|
Enterprise Value (EV)
1 |
4,602
|
6,691
|
107.5
|
437.6
|
68.02
|
34.75
|
-45.61
|
-16.54
|
P/E ratio
|
-
|
-45.2
x
|
-1.95
x
|
-1.66
x
|
-1.28
x
|
-0.76
x
|
-1.6
x
|
-1.53
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-51.2
x
|
-43
x
|
-0.4
x
|
-1.39
x
|
-
|
-0.22
x
|
0.75
x
|
0.27
x
|
EV / FCF
|
-
|
-58,413,250
x
|
-445,880
x
|
-
|
-
|
-
|
466,845
x
|
165,358
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
0%
|
0%
|
Price to Book
|
-
|
-
|
1.18
x
|
1.72
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
48,666
|
52,503
|
54,313
|
85,204
|
87,476
|
88,544
|
-
|
-
|
Reference price
2 |
95.36
|
140.0
|
9.790
|
8.420
|
2.730
|
1.185
|
1.185
|
1.185
|
Announcement Date
|
2/25/20
|
3/1/21
|
3/1/22
|
3/6/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-89.91
|
-155.5
|
-269.2
|
-315.4
|
-
|
-159.3
|
-61.12
|
-60.71
|
EBIT
1 |
-91.42
|
-157.1
|
-271.5
|
-322.4
|
-196.1
|
-147.3
|
-76.73
|
-94.18
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-269.9
|
-320
|
-185.7
|
-133.4
|
-75.51
|
-98.41
|
Net income
1 |
-
|
-153.5
|
-269.9
|
-320
|
-185.7
|
-138.3
|
-75.14
|
-93.57
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-3.100
|
-5.010
|
-5.060
|
-2.140
|
-1.564
|
-0.7414
|
-0.7720
|
Free Cash Flow
|
-
|
-114.6
|
-241.1
|
-
|
-
|
-
|
-97.7
|
-100
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
3/1/21
|
3/1/22
|
3/6/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-94.9
|
-193.5
|
-46.99
|
-30.13
|
-44.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-96.08
|
-195.7
|
-49.12
|
-31.44
|
-46.22
|
-45.05
|
-37.82
|
-48.21
|
-64.98
|
-45.72
|
-31.83
|
-23.96
|
-18.67
|
-14.69
|
-15.57
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-94.36
|
-197
|
-49.1
|
-30.84
|
-42.99
|
-42.4
|
-35.12
|
-45.63
|
-62.55
|
-71.15
|
-27.76
|
-18.72
|
-14.95
|
-11.48
|
-13.56
|
Net income
1 |
-94.36
|
-197
|
-49.1
|
-30.84
|
-42.99
|
-42.4
|
-35.12
|
-45.63
|
-62.55
|
-71.15
|
-30.02
|
-21.09
|
-17.18
|
-11.48
|
-13.56
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.730
|
-3.600
|
-0.9000
|
-0.5300
|
-0.5000
|
-0.4900
|
-0.4100
|
-0.5200
|
-0.7100
|
-0.8100
|
-0.3400
|
-0.2371
|
-0.1843
|
-0.1867
|
-0.2033
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/6/22
|
8/4/22
|
11/7/22
|
3/6/23
|
5/9/23
|
8/9/23
|
11/13/23
|
3/14/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
38.4
|
659
|
424
|
280
|
171
|
70.2
|
151
|
121
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-115
|
-241
|
-
|
-
|
-
|
-97.7
|
-100
|
ROE (net income / shareholders' equity)
|
-
|
-26.7%
|
-49.1%
|
-84.7%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
8.280
|
4.910
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-3.860
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.63
|
33.2
|
8.33
|
-
|
-
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
3/1/21
|
3/1/22
|
3/6/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
1.185
USD Average target price
2.9
USD Spread / Average Target +144.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -56.59% | 105M | | +7.52% | 113B | | +11.38% | 106B | | +1.22% | 22.27B | | -12.64% | 22.22B | | -4.73% | 19.43B | | -37.85% | 17.87B | | -8.58% | 17.24B | | +7.77% | 14.29B | | +37.41% | 12.52B |
Bio Therapeutic Drugs
|